Research progress in the intervention effect of traditional chinese medicine on targeted therapy for non-small cell lung cancer
FAN Rui1 LI He-gen2▲
1. Longhua Clinical Medical College Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200030, China；
2. The Third Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200030, China
Abstract：Non-small cell lung cancer (NSCLC) is one of the most common malignant tumors in China. Surgical treatment is the first choice for early and middle stage patients. Postoperative adjuvant radiotherapy and chemotherapy can prolong the survival time, but its efficacy has entered a plateau period. Molecular targeting therapy has made some progress in the treatment of advanced lung cancer, but targeting therapy has the dual characteristics of good effect and easy drug resistance, and can cause side effects such as diarrhea, rash and so on. The adjuvant treatment of traditional Chinese medicine can delay the drug resistance time of targeting drugs, efficacy enhancing and toxicity reducing of targeting therapy, and play the role of synergy and attenuation. In this review, by discussing the research process of targeted therapy and combining with the research progress of traditional Chinese medicine, we propose that TCM intervention can improve the clinical therapeutic effect from the perspective of integration of traditional Chinese medicine and Western medicine, and provide a theoretical basis for the treatment of diseases.
范瑞；李和根. 中医药对非小细胞肺癌靶向治疗干预作用的研究进展[J]. 中国当代医药, 2019, 26(9): 26-29转33.
FAN Rui；LI He-gen. Research progress in the intervention effect of traditional chinese medicine on targeted therapy for non-small cell lung cancer. 中国当代医药, 2019, 26(9): 26-29转33.
Szymanowska A，Jassem E，Dziadziuszko R，et al.Gefitinib or
CarboplatinΓ Co Paclitaxel in Pulmonary Adenocarcinoma[J].N Engl J Med，2009，361：947-957.
[4]
Shi Y，Li J，Zhang S，et al.Molecular epidemiology of egfr mutations in asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology-mainland china subset analysis of the PIONEER study[J].PLoS One，2015，10（11）：e0143515.
[5]
Kobayashi Y，Mitsudomi T.Not all epidermal growth factor receptor mutations in lung cancer are created equal：perspectives for individualized treatment strategy[J].Cancer Sci，2016，107（9）：1179-1186.
[6]
Sc huler M，Paz-Ares L，Sequist LV，et al.92PDFirst-line afatinib for advanced EGFR+NSCLC：analysis of long-term responders （LTRs） in the LUX-Lung （LL）3，6 and 7 trials[J].Ann Oncol，2017，28（S2）：142-146.
[7]
Lee CK，Davies L，Wu YL，et al.Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer：individual patient data meta-analysis of overall survival[J]J Natl Cancer Inst，2017，109（6）：856-862.
[8]
Morgillo F，Corte CMD，Fasano M，et al.Mechanisms of resistance to EGFR-targeted drugs：lung cancer[J].Esmo Open，2016，1（3）：e000060.
[9]
Wang S，Song Y，Yan F，et al.Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors[J].Front Med，2016，10（4）：383-388.
[10]
Goto K，Nishio M，Yamamoto N，et al.A prospective，phase II，open-label study （JO22903） of first-line erlotinib in Japanese patientswith epidermal growth factor receptor(EGFR) mutation-positive advanced non-small-cell lungcancer (NSCLC) [J]. Lung Cancer，2013,82（1）：109-114.
[11]
Wang S，Song Y，Liu D.EAI045：the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance[J].Cancer Lett，2016，385：51-54.
[12]
Soda M，Choi YL，Enomoto M，et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J].Nature，2007，448（7153）：561-566.
[13]
Nishi M，Kim DW，Wu YL，et al.Crizotinib versus chemotherapy in Asian patients with advanced ALK-positive nonsmall cell lung cancer[J].Cancer Res Treat，2017，50（3）：691-700.
[14]
Choi YL，Soda M，Yamashita Y，et al.EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors[J].N EngI J Med，2010，363（18）：1734-1739.
Kim DW，Mehra R，Tan SW，et al.Ceritinib in advanced anaplastic lymphoma kinase （ALK）-rearranged （ALK+）non-small cell lung cancer （NSCLC）：results of the ASCEND-1 trial[J].Oncologist，2014，19（10）：5-11.
[18]
Wu YL，Yang JC，Kim DW，et al.Phase Ⅱstudy of crizotinib in east asian patients with ROSL-positive advanced non-small-cell lung cancer[J].J Clin Oncol，2018，36（14）：1405-1411.
京公网安备 11010502046607号